Form 4: Relay Therapeutics Director Habib J. Dable Receives Options

Director Habib J. Dable was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Summary

• Habib J. Dable, a Director at Relay Therapeutics, Inc., was granted 32,947 stock options on June 9, 2026.
• The options have an exercise price of $14.09 per share.
• The options are set to expire on June 8, 2036.
• The grant vests in full on the earlier of the first anniversary of the grant date or the date of the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment as it does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $14.09 exercise price.

Future Outlook

The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, indicating a standard short-term retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced board members, aligning their compensation with the company's long-term clinical and commercial success.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of stock options as a primary incentive tool remains a standard governance practice for companies in the development stage.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of the options on the earlier of June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Relay Therapeutics, RLAY, Form 4, Insider Trading, Stock Options, Director Compensation